About Cancer Pain Therapeutics
Cancer pain can be acute or chronic, depending on its stages and types. Cancer pain is caused by the tumor pressing against bones, nerves, or other organs in an individuals body. Pain control is imperative not only for people who have advanced cancer but also for those whose condition remains stable for years. Pharmaceutical interventions such as non-steroidal anti-inflammatory drugs (NSAIDs), opioids, and adjuvant pain medications are used to treat cancer pain.
Technavios analysts forecast the global cancer pain therapeutics market to grow at a CAGR of 9.08% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global cancer pain therapeutics market for 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the treatment of cancer pain.
The market is divided into the following segments based on region:
Americas: The US, Canada, Mexico, and Brazil
EMEA: The UK, Germany, Italy, France, Spain, Israel, South Africa, Egypt, Sudan, Kuwait, Saudi Arabia, Qatar, and the UAE
APAC: Japan, China, Australia, Singapore, South Korea, and India
Technavios report, Global Cancer Pain Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
BioDelivery Sciences
ProStrakan Group
Teva Pharmaceuticals
Yamaha
Other prominent vendors
Daiichi Sankyo
Eli-lilly
Galena Biopharma
Grunenthal Group
GW Pharmaceuticals
Hospira
Johnson & Johnson
Meda Pharmaceuticals
Orexo
Sanofi
Sorrento Therapeutics
WEX Pharmaceuticals
Market driver
Unmet medical needs
For a full, detailed list, view our report
Market challenge
Off-label drug use
For a full, detailed list, view our report
Market trend
Increase in awareness
For a full, detailed list, view our report
Key questions answered in this report
What will the market size be in 2020 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analysts time when you purchase this market report. Details are provided within the report.
PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
Top-vendor offerings
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Introduction
Key market highlights
PART 05: Disease overview
Understanding the disease
Signs and symptoms
Causes of cancer pain
Assessment of cancer pain
Treatment
Epidemiology
PART 06: Pipeline portfolio
Information on pipeline candidates
PART 07: Market landscape
Market overview
Market size and forecast
Five forces analysis
PART 08: Market segmentation by drug class
Opioids
Non-steroidal anti-inflammatory drugs
Others
PART 09: Geographical segmentation
Cancer pain therapeutics market in Americas
Cancer pain therapeutics market in EMEA
Cancer pain therapeutics market in APAC
PART 10: Market drivers
PART 11: Impact of drivers
PART 12: Market challenges
PART 13: Impact of drivers and challenges
PART 14: Market trends
PART 15: Vendor landscape
Competitive scenario
Market analysis 2014
PART 16: Vendor landscape
Other prominent vendors
PART 17: Key vendor analysis
BioDelivery Sciences
ProStrakan
Teva Pharmaceuticals
PART 18: Appendix
List of abbreviations
PART 19: Explore Technavio
List Of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Classification of cancer pain
Exhibit 03: Acute pain syndromes
Exhibit 04: Chronic pain syndromes
Exhibit 05: Causes of pain from cancer
Exhibit 06: Causes of pain from procedures and surgery
Exhibit 07: Causes of pain from other cancer treatments
Exhibit 08: Common causes of pain in cancer patients
Exhibit 09: Cancer pain assessment
Exhibit 10: Types of pain scales
Exhibit 11: Treatment options for cancer pain
Exhibit 12: Commonly used non-opioids for pain management
Exhibit 13: Commonly used adjuvant medicines for cancer pain
Exhibit 14: Management of cancer pain
Exhibit 15: Pipeline molecules for cancer pain therapeutics market
Exhibit 16: Global cancer pain therapeutics market ($ millions)
Exhibit 17: Five forces analysis
Exhibit 18: Global cancer pain therapeutics market by drug class
Exhibit 19: Global cancer pain therapeutics market by geographical segmentation 2014
Exhibit 20: Cancer pain therapeutics market in different regions, 2014-2019 ($ millions)
Exhibit 21: Cancer pain therapeutics market in the Americas 2014-2019 ($ millions)
Exhibit 22: Cancer pain therapeutics market in EMEA 2014-2019 ($ millions)
Exhibit 23: Cancer pain therapeutics market in APAC 2014-2019 ($ millions)
Exhibit 24: Impact of drivers
Exhibit 25: Impact of drivers and challenges
Exhibit 26: BioDelivery Sciences: Key takeaways
Exhibit 27: ProStrakan: Key takeaways
Exhibit 28: Teva Pharmaceuticals: Key takeaways
Exhibit 29: BioDelivery Sciences: Product pipeline
Exhibit 30: Teva Pharmaceuticals: Business segmentation by revenue 2014
Exhibit 31: Teva Pharmaceuticals: Business segmentation by revenue 2013 and 2014 ($ millions)
Exhibit 32: Teva Pharmaceuticals: Geographical segmentation by revenue 2014
